Skip to main content

Table 2 Direct comparisons of SLIT and SCIT for efficacy

From: Sublingual immunotherapy: World Allergy Organization position paper 2013 update

Author, year design Ages (y) Treat-ment Dropouts Allergen Duration Cumulative doses Disease Main results
Eifan, 2010 [27] 5–12 16 SCIT 2 Mite 1 y SCIT 111 mg Der p 1/156 mg Der f 1 RA Significant reduction of total rhinitis and asthma score, medication score, VAS, and skin reactivity P < 0.05 versus pharmacotherapy for both SCIT and SLIT. No difference between routes of administration.
Randomized, open, controlled   16 SLIT 1
  16 CON 2
SLIT 295.5 mg Der p 1/f 1
Keles, 2011 [24] 5–12 15 SCIT 2 Mite 18 mo Der p 1: 53 mcg SLIT and 42 mcg SCIT A Decreased asthma attacks and use of steroids at 4, 12, 18 mo for SCIT and SCIT+SLIT, at 12 mo only for SLIT. No change in VAS for asthma with SCIT or SIT alone.
Double blind, double dummy, controlled   15 SLIT 2
15 SLIT 1
+ SCIT  
15 CON 3
Yukselen, 2012 [62] 7–14 10 SCIT 1 Mite 1 y 173,733 TU (86,866.5 TU D pt. and 86,866.5 TU Df). RA Significant reduction in symptom and medication score versus baseline with both treatments. SCIT better than SLIT versus placebo.
10 SLIT 1
Double blind, double dummy, placebo controlled
   10 PLA 0      
  1. Abbreviations: CON control, PLA placebo, SCIT subcutaneous immunotherapy, SLIT sublingual immunotheapy, RA Rhinitis with asthma, A asthma, VAS visual analog scale.